Protocol I6T-MC-AMAN: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1

Project: Research project

Project Details

StatusFinished
Effective start/end date4/1/20 → 6/30/22

Funding

  • Quintiles, Inc. (Protocol I6T-MC-AMAN)
  • Eli Lilly and Company (Protocol I6T-MC-AMAN)